aTyr Pharma (ATYR) awards CEO 1.5M options fully vesting through 2029

Rhea-AI Filing Summary

aTyr Pharma Inc. reported an insider equity award to its President and CEO, Sanjay Shukla. On January 9, 2026, he was granted an employee stock option for 1,500,000 shares of common stock at an exercise price of $0.7127 per share. The Form 4 shows the transaction as acquired and held directly, with 1,500,000 derivative securities beneficially owned after the grant.

The option will vest in 36 equal monthly installments beginning February 9, 2026, and is expected to be fully exercisable by January 9, 2029. The award agreement also provides for accelerated vesting if Dr. Shukla is terminated without cause in connection with a change of control of the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shukla Sanjay

(Last) (First) (Middle)

10240 SORRENTO VALLEY ROAD

SUITE 300

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$0.7127	01/09/2026		A		1,500,000		(1)	01/09/2036	Common Stock	1,500,000	$0	1,500,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

	/s/ Nancy E. Denyes, attorney-in-fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did aTyr Pharma (ATYR) disclose in this insider filing?

aTyr Pharma disclosed that its President and CEO, Sanjay Shukla, received an employee stock option covering 1,500,000 shares of common stock on January 9, 2026.

How many aTyr Pharma shares are covered by the CEO's new stock option?

The new employee stock option granted to CEO Sanjay Shukla covers 1,500,000 shares of aTyr Pharma common stock.

What is the exercise price of the aTyr Pharma CEO stock option granted on January 9, 2026?

The employee stock option granted to the CEO on January 9, 2026 has an exercise price of $0.7127 per share of common stock.

When do the aTyr Pharma CEO's stock options vest and become exercisable?

The shares subject to the option vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, and are expected to be fully exercisable on January 9, 2029.

Is there any accelerated vesting feature in the aTyr Pharma CEO option grant?

Yes. The option is subject to accelerated vesting if the CEO is terminated without cause in connection with a change of control of aTyr Pharma.

How is the CEO's ownership of these aTyr Pharma options reported?

The Form 4 reports 1,500,000 derivative securities beneficially owned by the CEO following the transaction, with ownership shown as direct.